Pre-Made Simlukafusp Alfa Biosimilar, Fusion Protein targeting FAP fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting DPPIV/FAPA/FAPalpha/SIMP for drug discovery and mechanism of action (MOA) research

Pre-Made Simlukafusp Alfa Biosimilar, Fusion Protein targeting FAP fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting DPPIV/FAPA/FAPalpha/SIMP is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Simlukafusp alfa (SIM; FAP-IL2v) is an interleukin-2 variant moiety fused to a human antibody against fibroblast activation protein-α (FAP). Simlukafusp alfa bind to FAP expressed on cancer-associated fibroblasts and mediates its accumulation in malignant lesions. Simlukafusp alfa retains binding affinity to IL-2 receptor βγ without binding to IL-2Rα resulting in activation of immune effector NK and CD8 T cells but not regulatory T cells. FAP-IL2v is designed to increase the pool of activated immune effector cells and is intended to be a combination partner to enhance the efficacy of cancer immunotherapies.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-991-1mg	1mg	3090
GMP-Bios-INN-991-10mg	10mg	Inquiry
GMP-Bios-INN-991-100mg	100mg	Inquiry
GMP-Bios-INN-991-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Simlukafusp Alfa Biosimilar, Fusion Protein targeting FAP fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting DPPIV/FAPA/FAPalpha/SIMP
INN Name	Simlukafusp Alfa
Target	FAP
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0